FR17C1058I2 - Compositions comprenant un antagoniste des opioides et bupropion pour influencer la perte de poids - Google Patents

Compositions comprenant un antagoniste des opioides et bupropion pour influencer la perte de poids

Info

Publication number
FR17C1058I2
FR17C1058I2 FR17C1058C FR17C1058C FR17C1058I2 FR 17C1058 I2 FR17C1058 I2 FR 17C1058I2 FR 17C1058 C FR17C1058 C FR 17C1058C FR 17C1058 C FR17C1058 C FR 17C1058C FR 17C1058 I2 FR17C1058 I2 FR 17C1058I2
Authority
FR
France
Prior art keywords
bupropion
compositions
weight loss
opioid antagonist
influence weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR17C1058C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orexigen Therapeutics Inc
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04760321A external-priority patent/EP1617832B1/en
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Publication of FR17C1058I1 publication Critical patent/FR17C1058I1/fr
Application granted granted Critical
Publication of FR17C1058I2 publication Critical patent/FR17C1058I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR17C1058C 2003-04-29 2017-12-08 Compositions comprenant un antagoniste des opioides et bupropion pour influencer la perte de poids Active FR17C1058I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46683803P 2003-04-29 2003-04-29
EP07116330A EP1870096A3 (en) 2003-04-29 2004-04-21 Compositions for affecting weight loss
EP04760321A EP1617832B1 (en) 2003-04-29 2004-04-21 Compositions for affecting weight loss

Publications (2)

Publication Number Publication Date
FR17C1058I1 FR17C1058I1 (OSRAM) 2018-01-12
FR17C1058I2 true FR17C1058I2 (fr) 2019-01-11

Family

ID=38719840

Family Applications (1)

Application Number Title Priority Date Filing Date
FR17C1058C Active FR17C1058I2 (fr) 2003-04-29 2017-12-08 Compositions comprenant un antagoniste des opioides et bupropion pour influencer la perte de poids

Country Status (6)

Country Link
EP (1) EP1870096A3 (OSRAM)
BE (1) BE2017C064I2 (OSRAM)
CY (2) CY1119418T1 (OSRAM)
FR (1) FR17C1058I2 (OSRAM)
LU (1) LUC00054I2 (OSRAM)
NL (1) NL300918I2 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012111011A2 (en) 2011-02-16 2012-08-23 Nir Barak Low dosage combinations of fluoxetine and reboxetine for treating obesity
EP2950799B1 (en) 2013-01-30 2019-12-04 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217353A (en) * 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
EP0782445B1 (en) * 1994-09-19 2002-03-13 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
CA2254116C (en) * 1996-05-07 2009-10-20 Ergo Research Corporation Method and composition for the treatment of lipid and glucose metabolism disorders
CA2318920A1 (en) * 1998-01-29 1999-08-05 James W. Young Pharmaceutical uses of optically pure (-)-bupropion
US6071918A (en) * 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
WO2001052851A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
DK1326630T3 (da) * 2000-09-18 2008-09-15 Sanos Bioscience As Anvendelse af GLP-2-peptider
US20030087896A1 (en) * 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
EP2074997A1 (en) * 2002-05-17 2009-07-01 Tioga Pharmaceuticals, Inc. Use of Asimadoline for the treatment of digestive disorders
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake

Also Published As

Publication number Publication date
BE2017C064I2 (OSRAM) 2023-08-09
CY2017041I2 (el) 2018-09-05
NL300918I1 (nl) 2017-12-14
CY1119418T1 (el) 2018-03-07
NL300918I2 (nl) 2018-01-09
EP1870096A2 (en) 2007-12-26
EP1870096A3 (en) 2011-04-20
CY2017041I1 (el) 2018-09-05
LUC00054I1 (OSRAM) 2017-12-13
LUC00054I2 (OSRAM) 2018-02-21
FR17C1058I1 (OSRAM) 2018-01-12

Similar Documents

Publication Publication Date Title
EP1755591A4 (en) OPHTHALMIC FORMULATIONS COMPRISING SELECTIVE ANTAGONISTS OF ALPHA RECEPTORS 1
ZA200702131B (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof l
FR2829022B1 (fr) Composition de fond de teint comprenant des pigments interferentiels
SG111310A1 (en) Lubricant compositions
EP1619970A4 (en) PURPOSE OF CLOTHING
FR2836389B3 (fr) Poids pour appareil de musculation
EP1806982A4 (en) COMPOSITIONS AND METHODS FOR PROMOTING IMPROVEMENT OF WEIGHT AND FEED AID
DE602004004278D1 (de) 4-cycloalkylaminopyrazolopyrimidin als nmda/nr2b-antagonisten
ATE403651T1 (de) 3-fluoro-piperidine als nmda/nr2b antagonisten
EP1617872A4 (en) METHODS AND COMPOSITIONS FOR ENHANCING AN IMMUNE RESPONSE
GB0303678D0 (en) Improvements in or relating to flavour compositions
FR17C1058I2 (fr) Compositions comprenant un antagoniste des opioides et bupropion pour influencer la perte de poids
GB2419373B (en) Improvements in or relating to an access platform
ITMI20031166A1 (it) Sedile per apparati di divertimento.
GB0327091D0 (en) Improvements in or relating to compositions
GB0312485D0 (en) Horse food composition
FR2865938B1 (fr) Formulation retard solide comprenant de l'acetate de triptoreline
DK1684715T3 (da) Sammensætninger omfattende neramexan
EP1811842A4 (en) IMMUNE ACTIVATION COMPOSITIONS BASED ON 3,3'-DIINDOLYLMETHANE
SG122048A1 (en) Lubricating compositions
GB0317398D0 (en) Improvements in or relating to an access platform
GB0303676D0 (en) Improvements in or relating to flavour compositions
GB0313682D0 (en) Cup trophy structure
GB0210486D0 (en) Improvements in or relating to transducer testing
GB2408578B (en) Improvements in or relating to metering